Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey

References

• Liu S, Liang Z, Nie J, et al. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1 [published online ahead of print, 2023 Jun 14]. Emerg Microbes Infect. 2023;12(2):2225638. doi:10.1080/22221751.2023.2225638
   PubMed Web of Science ®Google Scholar
• Lu S, Luo S, Bai B, et al. Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V. J Med Virol. 2023;95(8):e29031. doi:10.1002/jmv.29031
   PubMed Web of Science ®Google Scholar
• Abbasi J. What to know about EG.5, the latest SARS-CoV-2 “variant of interest” [published online ahead of print, 2023 Aug 18]. JAMA. 2023. doi:10.1001/jama.2023.16498
   Web of Science ®Google Scholar
• Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023;401(10377):664–672. doi:10.1016/S0140-6736(23)00129-0
   PubMed Web of Science ®Google Scholar
• Liu J, Liu M, Liang W. The dynamic COVID-zero strategy in China. China CDC Wkly. 2022;4(4):74–75. doi:10.46234/ccdcw2022.015
   PubMedGoogle Scholar
• He Y, Zhang F, Liu Y, et al. Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy. Vaccines (Basel). 2023;11(5):968. doi:10.3390/vaccines11050968
   PubMed Web of Science ®Google Scholar
• Wang M, Liu Z, Wang Z, et al. Clinical characteristics of 1139 mild cases of the SARS-CoV-2 omicron variant infected patients in Shanghai. J Med Virol. 2023;95(1):e28224. doi:10.1002/jmv.28224
   PubMed Web of Science ®Google Scholar
• Garrett N, Tapley A, Andriesen J, et al. High asymptomatic carriage With the omicron variant in South Africa. Clin Infect Dis. 2022;75(1):e289–e292. doi:10.1093/cid/ciac237
   PubMed Web of Science ®Google Scholar
• Yu W, Guo Y, Zhang S, et al. Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 omicron variant: a systematic review and analysis. J Med Virol. 2022;94(12):5790–5801. doi:10.1002/jmv.28066
   PubMed Web of Science ®Google Scholar
• Blom K, Havervall S, Marking U, et al. Infection rate of SARS-CoV-2 in asymptomatic healthcare workers, Sweden, June 2022. Emerg Infect Dis. 2022;28(10):2119–2121. doi:10.3201/eid2810.221093
   PubMed Web of Science ®Google Scholar
• Graydon EK, Malloy AMW, Machmach K, et al. High baseline frequencies of natural killer cells are associated with asymptomatic SARS-CoV-2 infection. Curr Res Immunol. 2023;4:100064. Published 2023 Jul 15. doi:10.1016/j.crimmu.2023.100064
   PubMedGoogle Scholar
• Durstenfeld MS, Peluso MJ, Peyser ND, et al. Factors associated With long COVID symptoms in an online cohort study. Open Forum Infect Dis. 2023;10(2):ofad047. doi:10.1093/ofid/ofad047
   PubMed Web of Science ®Google Scholar
• Freeman ML, Oyebanji OA, Moisi D, et al. Association of cytomegalovirus serostatus With severe acute respiratory syndrome coronavirus 2 vaccine responsiveness in nursing home residents and healthcare workers. Open Forum Infect Dis. 2023;10(2):ofad063. doi:10.1093/ofid/ofad063
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tabernero J, Mukherjee U, et al. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Lancet Oncol. 2023;24(4):335–346. doi:10.1016/S1470-2045(23)00056-6
   PubMed Web of Science ®Google Scholar
• Wang L, Gao GF. No novel prevalent mutations detected in the circulating strains of BF.7, BA.5.2, DY, and XBB - China, November 2022 to June 2023. China CDC Wkly. 2023;5(30):672–673. doi:10.46234/ccdcw2023.126
   PubMedGoogle Scholar
• Rahman MM, Akash S, Islam MR. SARS-CoV-2 new variant BF.7: a new public threat globally, symptoms, precautions, transmission rate, and futures perspective - correspondence. Int J Surg. 2023;109(2):181–183. doi:10.1097/JS9.0000000000000173
   PubMed Web of Science ®Google Scholar
• Huo D, Yu T, Shen Y, et al. A comparison of clinical characteristics of infections with SARS-CoV-2 omicron subvariants BF.7.14 and BA.5.2.48 – China, October-December 2022. China CDC Wkly. 2023;5(23):511–515. doi:10.46234/ccdcw2023.096
   PubMedGoogle Scholar
• Zhang M, Wang Y, Zhang T, et al. Status of and perspectives on COVID-19 vaccination after lifting of the dynamic zero-COVID policy in China. Glob Health Med. 2023;5(2):112–117. doi:10.35772/ghm.2022.01063
   PubMedGoogle Scholar
• Dai L, Duan H, Liu X, et al. Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection [published online ahead of print, 2023 Aug 14]. Lancet. 2023;S0140-6736(23):01367–3. doi:10.1016/S0140-6736(23)01367-3
   Google Scholar
• Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2023;29(1):226–235. doi:10.1038/s41591-022-02116-3
   PubMedGoogle Scholar
• Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations [published correction appears in Nat Rev microbiol. 2023 Jun;21(6):408]. Nat Rev Microbiol. 2023;21(3):133–146. doi:10.1038/s41579-022-00846-2
   PubMed Web of Science ®Google Scholar
• Cai J, Lin K, Zhang H, et al. A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China. Emerg Microbes Infect. 2023;12(2):2220578. doi:10.1080/22221751.2023.2220578
   PubMed Web of Science ®Google Scholar
• Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097–2111. doi:10.1056/NEJMoa2202261
   PubMed Web of Science ®Google Scholar
• Zheng H, Cao Y, Chen X, et al. Disease profile and plasma neutralizing activity of post-vaccination omicron BA.1 infection in Tianjin, China: a retrospective study. Cell Res. 2022;32(8):781–784. doi:10.1038/s41422-022-00674-2
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854. doi:10.1016/S0140-6736(20)31208-3
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289. doi:10.1038/s41586-021-03275-y
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Nouhin J, et al. SARS-CoV-2 antiviral therapy. Clin Microbiol Rev. 2021;34(4):e0010921. doi:10.1128/CMR.00109-21
   PubMed Web of Science ®Google Scholar
• Qin S, Li W, Shi X, et al. Cases reveal important prognosis signatures of COVID-19 patients. Comput Struct Biotechnol J. 3044;2021(19):1163–1175. doi:10.1016/j.csbj.2021.01.042
   Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Cheong HH, Sio FI, Chan CC, et al. Clinical characteristics of COVID-19 patients infected by the omicron variants in Macao, China: a cross-sectional study. Health Sci Rep. 2023;6(7):e1361. doi:10.1002/hsr2.1361
   PubMedGoogle Scholar
• Chen X, Li Y, Shao TR, et al. Some characteristics of clinical sequelae of COVID-19 survivors from Wuhan, China: a multi-center longitudinal study. Influenza Other Respir Viruses. 2022;16(3):395–401. doi:10.1111/irv.12943
   PubMed Web of Science ®Google Scholar
• Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023;401(10393):e21–e33. doi:10.1016/S0140-6736(23)00810-3
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang C, Jing Q, et al. Follow-up of patients with COVID-19 by the delta variant after hospital discharge in Guangzhou, Guandong, China. Rev Inst Med Trop Sao Paulo. 2022;64:e31. doi:10.1590/s1678-9946202264031
   PubMed Web of Science ®Google Scholar
• Hedberg P, Karlsson Valik J, van der Werff S, et al. Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data. Thorax. 2022;77(2):154–163. doi:10.1136/thoraxjnl-2021-216949
   PubMed Web of Science ®Google Scholar
• Duan M, Duan H, An Y, et al. A booster of delta-omicron RBD-dimer protein subunit vaccine augments sera neutralization of omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5. Emerg Microbes Infect. 2023;12(1):e2179357. doi:10.1080/22221751.2023.2179357
   PubMed Web of Science ®Google Scholar
• Huang T, Zhang S, Dai DF, et al. Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study. Lancet Respir Med. 2023;11(8):698–708. doi:10.1016/S2213-2600(23)00129-7
   PubMed Web of Science ®Google Scholar